Major Clinical Setback: Harmony Biosciences' Genetic Disorder Drug Disappoints in Crucial Phase 3 Study
Harmony Bio Faces Significant Setback: Fragile X Syndrome Therapy Misses Primary Endpoint in Pivotal Trial